ARROWHEAD PHARMACEUTICALS, INC. Variable Lease, Cost
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Variable Lease, Cost of $200.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2022-08-04
- ARROWHEAD PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2022-06-30 was $200.00K, a 100.00% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2022-03-31 was $100.00K, a 50.00% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2021-12-31 was $200.00K, a 0.00% change year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2021-09-30 was $200.00K, a 0.00% change year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. variable lease, cost for fiscal 2021 was $800.00K, a 0.00% change from fiscal 2020.
- ARROWHEAD PHARMACEUTICALS, INC. variable lease, cost for fiscal 2020 was $800.00K, a 60.00% increase from fiscal 2019.
- ARROWHEAD PHARMACEUTICALS, INC. variable lease, cost for fiscal 2019 was $500.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2022-06-30 | $200.00K 10-Q · filed 2022-08-04 | $300.00K derived: sum of 2 quarters · filed 2022-08-04 | $500.00K 10-Q · filed 2022-08-04 | $700.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-10 | $300.00K 10-Q · filed 2022-05-10 | $500.00K derived: sum of 3 quarters · filed 2022-05-10 | $600.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-12-31 | $200.00K 10-Q · filed 2022-02-02 | $400.00K derived: sum of 2 quarters · filed 2022-02-02 | $500.00K derived: sum of 3 quarters · filed 2022-08-04 | $700.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-09-30 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22 | $300.00K derived: sum of 2 quarters · filed 2022-08-04 | $500.00K derived: sum of 3 quarters · filed 2022-08-04 | $800.00K 10-K · filed 2021-11-22 |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-04 | $300.00K derived: sum of 2 quarters · filed 2022-08-04 | $600.00K 10-Q · filed 2022-08-04 | $700.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-10 | $500.00K 10-Q · filed 2022-05-10 | $600.00K derived: sum of 3 quarters · filed 2022-05-10 | $800.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $200.00K 10-Q · filed 2022-02-02 | $400.00K derived: sum of 2 quarters · filed 2022-02-02 | $600.00K derived: sum of 3 quarters · filed 2022-02-02 | $800.00K derived: sum of 4 quarters · filed 2022-02-02 |
| 2020-09-30 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22 | $400.00K derived: sum of 2 quarters · filed 2021-11-22 | $600.00K derived: sum of 3 quarters · filed 2021-11-22 | $800.00K 10-K · filed 2021-11-22 |
| 2020-06-30 | $200.00K 10-Q · filed 2021-08-05 | $400.00K derived: sum of 2 quarters · filed 2021-08-05 | $600.00K 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-04 | $300.00K 10-Q · filed 2021-05-04 | ||
| 2019-12-31 | $200.00K 10-Q · filed 2021-02-04 | |||
| 2019-09-30 | $500.00K 10-K · filed 2021-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |